Two Neuropeptides Could Address Both Inflammation and Nerve Damage in MS | Research

The takeaway

VIP and PACAP are neuropeptides with both anti-inflammatory and nerve-protecting properties that show promise for treating both aspects of multiple sclerosis in animal models.

Dual anti-inflammatory + neuroprotective action
VIP and PACAP are among the few therapeutic candidates that can address both the immune attack and nerve damage in MS simultaneously

What the researchers found

VIP (vasoactive intestinal peptide) and PACAP (pituitary adenylate cyclase-activating peptide) have dual properties that make them attractive therapeutic candidates for multiple sclerosis: they are both potent anti-inflammatory agents and neuroprotective molecules. Both peptides showed significant activity in the EAE (experimental autoimmune encephalomyelitis) animal model of MS.

Current MS drugs primarily target the immune system and work well at early stages but do little to prevent the neurodegeneration that causes permanent disability. VIP and PACAP could potentially address both components — calming the autoimmune attack and directly protecting nerve cells from damage. The review extensively maps the structure-activity relationships of these peptides with their receptors, laying groundwork for designing improved analogs.

Why it matters

Multiple sclerosis affects approximately 2.5 million people worldwide, and current treatments largely fail to prevent the neurodegenerative component that causes permanent disability. VIP and PACAP represent a fundamentally different therapeutic approach because they simultaneously address inflammation and neurodegeneration — the two hallmarks of MS. Understanding how these peptides interact with their receptors at the molecular level is essential for developing stable, drug-like analogs that could reach clinical trials.

The numbers in context

~2.5 million MS patients worldwide · EAE animal model data · VIP and PACAP both active · Dual anti-inflammatory + neuroprotective mechanisms

How the study worked

This is a comprehensive narrative review covering the immunomodulatory and neuroprotective properties of VIP and PACAP, their receptor signaling pathways, and extensive structure-activity relationship data. It synthesizes evidence from animal models of MS (EAE), in vitro studies, and biophysical interaction studies of peptide-receptor binding.

Who was studied

Review of preclinical research (animal models and in vitro studies) relevant to multiple sclerosis

What this study cannot tell us

All MS-related efficacy data discussed comes from animal models (EAE), not human clinical trials. VIP and PACAP have short half-lives in the body, which is a major obstacle to therapeutic use. The review is from 2011, and the MS treatment landscape has changed significantly with newer disease-modifying therapies.

How to read the evidence

This is a preliminary-grade review because all MS efficacy evidence comes from animal models. No human clinical trials of VIP or PACAP for MS are discussed. The structure-activity data is thorough but translational relevance remains unproven.

When this study was published

Published in 2011, this review predates several major MS drug approvals (ocrelizumab, siponimod, ofatumumab). The MS treatment landscape has evolved substantially, though the unmet need for neuroprotective therapies remains.

The bigger picture

This review represents an important chapter in the search for MS treatments that go beyond immune suppression. While VIP and PACAP themselves haven't become MS drugs due to stability and delivery challenges, the concept of dual anti-inflammatory/neuroprotective therapy has gained traction. The receptor-level insights from this review have informed ongoing efforts to design stable peptide analogs and small-molecule mimetics that could eventually reach clinical trials for MS and other neuroinflammatory conditions.

Questions still open

Can stable VIP or PACAP analogs be developed that maintain both anti-inflammatory and neuroprotective effects?
Would VIP/PACAP receptor agonists be effective in progressive MS where neurodegeneration dominates?
How do VIP and PACAP compare to newer MS therapies that have emerged since 2011?

Common questions

What makes VIP and PACAP different from current MS drugs?

Current MS drugs mainly suppress the immune system to slow disease progression. VIP and PACAP do that too, but they also directly protect nerve cells from damage — the aspect of MS that causes permanent disability. This dual action could theoretically address both the cause and the consequence of the disease.

Why aren't VIP and PACAP used as MS treatments already?

Both peptides break down very quickly in the body, making them impractical as drugs in their natural form. Researchers are working on developing modified versions (analogs) that maintain the therapeutic properties while lasting long enough to be useful as medications. So far, no VIP or PACAP-based drug has reached clinical trials for MS.

Read the original research

Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

ASN neuro, 3(4)

View on PubMed ↗Publisher’s paper ↗

Citation

Tan, Yossan-Var; Waschek, James A. (2011). Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.. ASN neuro, 3(4). https://doi.org/10.1042/AN20110024